A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Sanofi

Status and phase: Completed; Phase 2

Conditions: Influenza; Swine-origin A/H1N1 Influenza

Treatments: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA); Biological: Normal saline solution (placebo); Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA); Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00953524

FUF14

UTN: U1111-1111-4798 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine.

Primary Objectives:

• To describe the immunogenicity of the candidate vaccines after each injection.
• To describe the safety of the candidate vaccines after each injection.

Full description

Participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively.

Enrollment: 849 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

• Healthy adults aged 18 years or older on the day of inclusion
• Informed consent has been signed and dated
• Able to attend all scheduled visits and comply with all trial procedures
• For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination, until at least 4 weeks after last vaccination.

Exclusion Criteria :

• Known pregnancy or positive urine pregnancy test
• Currently breastfeeding a child
• Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
• Planned participation in another clinical trial during the present trial period
• Receipt of any vaccine in the 4 weeks preceding the trial vaccination
• Planned receipt of any vaccine prior to the Day 42 blood sample
• Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response
• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
• Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination
• Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
• Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
• Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator.
• Previous participation in a swine-origin H1N1 pandemic flu trial except if performed in 1976
• Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March 2009
• Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination
• Personal or family history of Guillain-Barré syndrome
• Active neoplastic disease or a history of any hematologic malignancy
• Known seizure/epilepsy history and/or taking anti-seizure medication
• Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and stable for at least 3 months prior to enrollment, without decompensating symptoms will be allowed to enroll in the study

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

849 participants in 4 patient groups, including a placebo group

A/H1N1 Vaccine Group 1

Experimental group

Description:

Participants will receive A/H1N1 vaccine formulation 1

Treatment:

Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)

A/H1N1 Vaccine Group 2

Experimental group

Description:

Participants will receive A/H1N1 vaccine formulation 2

Treatment:

Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)

A/H1N1 Vaccine Group 3

Experimental group

Description:

Participants will receive A/H1N1 Vaccine formulation 3

Treatment:

Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)

Placebo Group

Placebo Comparator group

Description:

Participants will receive a placebo vaccine

Treatment:

Biological: Normal saline solution (placebo)